全文获取类型
收费全文 | 202篇 |
免费 | 10篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 55篇 |
基础医学 | 15篇 |
临床医学 | 12篇 |
内科学 | 35篇 |
皮肤病学 | 3篇 |
神经病学 | 13篇 |
特种医学 | 2篇 |
外科学 | 46篇 |
预防医学 | 3篇 |
药学 | 17篇 |
肿瘤学 | 11篇 |
出版年
2023年 | 1篇 |
2022年 | 4篇 |
2021年 | 9篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 3篇 |
2016年 | 1篇 |
2015年 | 7篇 |
2014年 | 4篇 |
2013年 | 12篇 |
2012年 | 14篇 |
2011年 | 18篇 |
2010年 | 21篇 |
2009年 | 19篇 |
2008年 | 10篇 |
2007年 | 13篇 |
2006年 | 6篇 |
2005年 | 15篇 |
2004年 | 8篇 |
2003年 | 9篇 |
2002年 | 8篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1996年 | 1篇 |
1987年 | 2篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1967年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有214条查询结果,搜索用时 31 毫秒
1.
Jun Guo Fu Wang Qing Zhou Qiang Geng Qinghe Gao Rui Zhang Chunhe Zhang Zhihua Xuan Jian Cai Bin Bin Qiang Han Boda Guo Bin Yan Jiwei Zhang Elena Colonnello Emmanuele A. Jannini 《Andrologia》2021,53(1):e13915
To evaluate the safety and efficacy of Chinese medicine, Qiaoshao formula combined with dapoxetine was used for the treatment of premature ejaculation in a real-life setting. Nine hundred and five males diagnosed with premature ejaculation were reviewed in this retrospective cohort study. We divided the patients into two groups: dapoxetine alone and Qiaoshao formula combined with dapoxetine according to actual interventions provided to patients in clinics. The perceived intravaginal ejaculation latency time and the premature ejaculation profile measures markedly improved in both groups. However, in men with severe premature ejaculation (baseline perceived intravaginal ejaculation latency time <1 min) and those with baseline age ≤30 years, the perceived intravaginal ejaculation latency time was slightly but significantly longer with combined therapy than with dapoxetine alone (p < .05). Therefore, combined therapy involving the Qiaoshao formula and dapoxetine proved to safe as well as effective for treating premature ejaculation while prolonging the perceived intravaginal ejaculation latency time, which significantly improved the overall satisfaction of the patient and likely that of the couple. 相似文献
2.
Emmanuele A. Jannini Alberto Rubio‐Casillas Beverly Whipple Odile Buisson Barry R. Komisaruk Stuart Brody 《The journal of sexual medicine》2012,9(4):956-965
IntroductionThere is general agreement that it is possible to have an orgasm thru the direct simulation of the external clitoris. In contrast, the possibility of achieving climax during penetration has been controversial.MethodsSix scientists with different experimental evidence debate the existence of the vaginally activated orgasm (VAO).Main Outcome MeasureTo give reader of The Journal of Sexual Medicine sufficient data to form her/his own opinion on an important topic of female sexuality.ResultsExpert #1, the Controversy's section Editor, together with Expert #2, reviewed data from the literature demonstrating the anatomical possibility for the VAO. Expert #3 presents validating women's reports of pleasurable sexual responses and adaptive significance of the VAO. Echographic dynamic evidence induced Expert # 4 to describe one single orgasm, obtained from stimulation of either the external or internal clitoris, during penetration. Expert #5 reviewed his elegant experiments showing the uniquely different sensory responses to clitoral, vaginal, and cervical stimulation. Finally, the last Expert presented findings on the psychological scenario behind VAO.ConclusionThe assumption that women may experience only the clitoral, external orgasm is not based on the best available scientific evidence. Jannini EA, Rubio‐Casillas A, Whipple B, Buisson O, Komisaruk BR, and Brody S. Female orgasm(s): one, two, several. J Sex Med 2012;9:956–965. 相似文献
3.
Stefano?Carlone Michele?Minenna Paride?Morlino Luigi?Mosca Franco?Pasqua Riccardo?Pela Pietro?Schino Alberto?Tubaldi Emmanuele?Tupputi Fernando?De BenedettoEmail author the Buccalin Trial Group 《Multidisciplinary respiratory medicine》2014,9(1):58
Background
(Buccalin ®) is a Bacterial Lysates (BL) that belongs to a family of immune-stimulators, developed more than 30 years ago and it still has a role in the prophylaxis of Recurrent Respiratory Tract Infections (RRTI). However, original studies were conducted with an approach that does not seem to be aligned with the present methodologies. In addition, concomitant therapies substantially improved in the last decades. These two reasons strongly suggested to update our knowledge on the capacity of this bacterial lysate (Buccalin ®) to reduce the number of days with infectious episodes in patients with RRTI.Methods
A double blind, placebo-controlled, randomized, multicentre study was programmed (EudraCT code: 2011-005187-25). The reduction of the number of days with infectious episodes (IE) was the primary endpoint. Secondary endpoints were the number of IE, the use of concomitant drugs, the efficacy on signs and symptoms of RRTI and the safety of the drug. Patients were treated according to the registered schedule and were followed up for a period of 6 months.Results
From a cohort of 188 patients eligible for the study, 90 were included in the active group and 88 in the placebo group. The study was completed in 170 patients. A significant reduction of the number of days with IE was observed (6.57 days in the active group and 7.47 in the placebo group). Secondary endpoints were only partially achieved. No virtual adverse events related to the treatment were recorded.Conclusion
The administration of bacterial lysate (Buccalin ®) in patients with RRTI had the capacity to significantly reduce the number of days with IE in a multicentre, randomized, placebo controlled, clinical study. The treatment was safe. Of note, all patients were free to be treated with the best concomitant therapies. In these conditions, the positive results observed demonstrated that this bacterial lysate has maintained its capacity of reducing the days with infections in patients with RRTI, also in association to the concomitant therapies available nowadays.4.
5.
Arzu Oezcelik Shahin Ayazi Steven R. DeMeester Joerg Zehetner Emmanuele Abate Joie Dunn Kimberly S. Grant John C. Lipham Jeffrey A. Hagen Tom R. DeMeester 《Journal of gastrointestinal surgery》2013,17(6):1032-1035
Introduction
Practitioners have noted a striking increase in the number of young patients under the age of 40 years old who develop esophageal adenocarcinoma. The aim of this study was to characterize the presentation, pathology and therapeutic outcome of these young patients.Methods
The records of patients who presented to the Foregut Surgical Service at the University of Southern California with esophageal adenocarcinoma between 2000 and 2007 were retrospectively reviewed. The presentation, tumor stage and histology, therapy and outcome of the patients under the age of 40 were compared to those ≥40.Results
Of the 374 patients reviewed, 20 (5 %) were under the age of 40. There were two patients in their second and 18 in their third decade of life. The youngest patient was 25 years old. A history of gastroesophageal reflux disease or Barrett’s esophagus was less common in patients <40 than in those ≥40; 15 and 5 % compared to 61 and 46 %. Similarly, patients <40 had a significantly longer time interval between the onset of symptoms and the diagnosis of their cancer than those ≥40; 4.5 vs. 2 months, p?=?0.04. They also had a higher prevalence of stage IV disease (30 vs. 6 %, p?=?0.0003), a shorter time to recurrence (9.5 vs.19 month, p?=?0.002), and a poorer median survival (17 vs. 43 month, p?=?0.04).Conclusion
Esophageal adenocarcinoma in patients <40 years old commonly presents with an advanced stage of the disease and an associated poor survival. This is likely due to a low index of suspicion that dysphagia seen in younger patients is due to a malignancy. 相似文献6.
Adapter protein SH2-Bbeta stimulates actin-based motility of Listeria monocytogenes in a vasodilator-stimulated phosphoprotein (VASP)-dependent fashion
下载免费PDF全文
![点击此处可从《Infection and immunity》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Diakonova M Helfer E Seveau S Swanson JA Kocks C Rui L Carlier MF Carter-Su C 《Infection and immunity》2007,75(7):3581-3593
SH2-Bbeta (Src homology 2 Bbeta) is an adapter protein that is required for maximal growth hormone-dependent actin reorganization in membrane ruffling and cell motility. Here we show that SH2-Bbeta is also required for maximal actin-based motility of Listeria monocytogenes. SH2-Bbeta localizes to Listeria-induced actin tails and increases the rate of bacterial propulsion in infected cells and in cell extracts. Furthermore, Listeria motility is decreased in mouse embryo fibroblasts from SH2-B(-/-) mice. Both recruitment of SH2-Bbeta to Listeria and SH2-Bbeta stimulation of actin-based propulsion require the vasodilator-stimulated phosphoprotein (VASP), which binds ActA at the surfaces of Listeria cells and enhances bacterial actin-based motility. SH2-Bbeta enhances actin-based movement of ActA-coated beads in a biomimetic actin-based motility assay, provided that VASP is present. In vitro binding assays show that SH2-Bbeta binds ActA but not VASP; however, binding to ActA is greater in the presence of VASP. Because VASP also plays an essential regulatory role in actin-based processes in eukaryotic cells, the present results provide mechanistic insight into the functions of both SH2-Bbeta and VASP in motility and also increase our understanding of the fundamental mechanism by which Listeria spreads. 相似文献
7.
8.
Barbagallo CM Emmanuele G Cefalù AB Fiore B Noto D Mazzarino MC Pace A Brogna A Rizzo M Corsini A Notarbartolo A Travali S Averna MR 《Atherosclerosis》2003,166(2):395-400
We describe a Sicilian family presenting a recessive form of hypercholesterolemia harboring a mutation of the autosomal recessive hypercholesterolemia (ARH) gene. In two of the three sibs, a 26-year-old male and a 22-year-old female, a severe hypercholesterolemia was diagnosed with very high levels of plasma cholesterol (15.9 and 12.2 mmol/l, respectively); tendon xanthomatas and xanthelasms were present and in the male proband was documented a diffuse coronary atherosclerotic disease with a rapid and fatal progression. Both the parents had normal or slightly increased levels of plasma cholesterol. All causes of secondary hypercholesterolemia were ruled out as well as an involvement of the LDL receptor or apoB genes. Beta-Sitosterol plasma levels were in the normal range. Cultured fibroblasts from skin biopsy from parents and the two probands displayed a normal ability to bind and degrade 125I-LDL. Direct sequencing of ARH gene demonstrated the presence of a 432insA mutation in homozygosis in the two probands; parents were heterozygotes for the same mutation. This mutation is the first report of a mutation of the ARH gene responsible for recessive forms of hypercholesterolemia in Sicily. 相似文献
9.
10.
Alessio Facciol Emmanuele Venanzi Rullo Manuela Ceccarelli Flavia D'Andrea Mariagiovanna Coco Cristina Micali Bruno Cacopardo Andrea Marino Serafinella P. Cannav Michelino Di Rosa Fabrizio Condorelli Giovanni F. Pellican Claudio Guarneri Giuseppe Nunnari 《Dermatologic therapy》2020,33(1)
People affected by immunodeficiency, and especially those infected by HIV, are burdened by a higher risk of developing malignancies. It has been estimated that the incidence of melanoma in HIV‐infected people is 2.6‐fold higher than in uninfected ones. In this group of patients, melanoma shows a more aggressive phenotype and poorer survival rates compared to HIV‐negative people. Standard guidelines of diagnosis and care do not exist yet. Studies suggest high index of suspicion and a low threshold for biopsy in HIV‐positive patients regardless of their CD4+ count and the use of standard surgical margins for re‐excision procedures. In case of diagnosis of melanoma in HIV‐positive patients, a thorough search for metastatic disease is recommended because of the more aggressive course of this cancer in HIV‐positive patients. Moreover, to rapidly find out any recurrence or metastatic disease after treatment, these patients need a close follow‐up, every 3 months, for the first 2 years and at least twice yearly thereafter. Although surgery remains the main therapeutic option, application of immune checkpoint‐based immunotherapy is being studied and seems to be promising. The aim of this review is to present the current knowledge and future options for melanoma diagnosis and treatment in people living with HIV. 相似文献